Richard A. Heyman, PhD

Richard A. Heyman, PhD

Metacrine, Inc.; ORIC Pharmaceuticals

Dr. Heyman is a co-founder and serves as executive chairman of Metacrine, Inc., a biotech company developing therapeutics for the treatment of diabetes and other metabolic disorders. He also serves as interim CEO and a board member of ORIC Pharmaceuticals, a biotech company focused on developing therapeutics that target treatment-resistant cancers. Previously, he served as CEO of Seragon Pharmaceuticals, co-founded and was CEO of Aragon Pharmaceuticals, and also co-founded and served as chief scientific officer of X-Ceptor Therapeutics. Heyman serves on the boards of the Salk Institute for Biological Studies, Organovo, Inc., Gritstone Oncology, and the UC San Diego Moores Cancer Center.